Although pioglitazone is now generically available and more cost-effective than a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a GLP-1 receptor agonist for CV protection, more clinical data may be needed to support the protective effects of pioglitazone against stroke in patients with type 2 DM and no established CV diseases. This evidence concerns the gene GLP1R and stroke disorder.